[
  {
    "ts": null,
    "headline": "Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis",
    "summary": "On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose com",
    "url": "https://finnhub.io/api/news?id=b06caa8f13f76bebffd3c10da3f02482f869c1f67f081f2a81c49a6676e37d40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734462936,
      "headline": "Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis",
      "id": 132034587,
      "image": "https://media.zenfs.com/en/Benzinga/9a26128de1065be03450fc9473d2a4dc",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program. Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose com",
      "url": "https://finnhub.io/api/news?id=b06caa8f13f76bebffd3c10da3f02482f869c1f67f081f2a81c49a6676e37d40"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock remains steady Tuesday, still outperforms market",
    "summary": "Merck & Co. Inc. stock remains steady Tuesday, still outperforms market",
    "url": "https://finnhub.io/api/news?id=b241400cc2cc3a47fcc9a0dd1da2d00e2effe76abc215b7473bf0aa943ab68d6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453300,
      "headline": "Merck & Co. Inc. stock remains steady Tuesday, still outperforms market",
      "id": 132065117,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock remains steady Tuesday, still outperforms market",
      "url": "https://finnhub.io/api/news?id=b241400cc2cc3a47fcc9a0dd1da2d00e2effe76abc215b7473bf0aa943ab68d6"
    }
  },
  {
    "ts": null,
    "headline": "Correction to Merck Gets FDA Review of Clesrovimab Article",
    "summary": "Merck's clesrovimab is an immunization aimed at protecting infants from respiratory syncytial virus, or RSV, disease. Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate, at 7:11 a.m. ET,...",
    "url": "https://finnhub.io/api/news?id=1b1babe83f84c081cd4e9dbfdf6d0a08b21d15a5d9ae224ee2556e5cdb0b9cd8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734441251,
      "headline": "Correction to Merck Gets FDA Review of Clesrovimab Article",
      "id": 132027672,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck's clesrovimab is an immunization aimed at protecting infants from respiratory syncytial virus, or RSV, disease. Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate, at 7:11 a.m. ET,...",
      "url": "https://finnhub.io/api/news?id=1b1babe83f84c081cd4e9dbfdf6d0a08b21d15a5d9ae224ee2556e5cdb0b9cd8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate",
    "summary": "Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate",
    "url": "https://finnhub.io/api/news?id=378306648a61c6e6fa75f1ff1ab5cb2e6f4ce2a98ab57ac4e43e403a68b24a74",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734440280,
      "headline": "Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate",
      "id": 132065118,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Gets FDA Review of Clesrovimab RSV Immunization Candidate",
      "url": "https://finnhub.io/api/news?id=378306648a61c6e6fa75f1ff1ab5cb2e6f4ce2a98ab57ac4e43e403a68b24a74"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
    "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have […]",
    "url": "https://finnhub.io/api/news?id=82f99bccbafbbd60da6693ce6b70d2f5c28ebb37296fa05c9b5861c09e4dbfca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734437904,
      "headline": "Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
      "id": 132025325,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have […]",
      "url": "https://finnhub.io/api/news?id=82f99bccbafbbd60da6693ce6b70d2f5c28ebb37296fa05c9b5861c09e4dbfca"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season",
    "summary": "RAHWAY, N.J., December 17, 2024--FDA Accepts BLA for Clesrovimab, Merck's Investigational Long-Acting MAb Designed to Protect Infants from RSV During their First RSV Season",
    "url": "https://finnhub.io/api/news?id=b3c7b91450ed17a018a90770455a683162147cf1fb23ba29b947d00ff060a0ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734435900,
      "headline": "Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season",
      "id": 132025326,
      "image": "https://media.zenfs.com/en/business-wire.com/7babdec6adee9eaab76df550f913be87",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 17, 2024--FDA Accepts BLA for Clesrovimab, Merck's Investigational Long-Acting MAb Designed to Protect Infants from RSV During their First RSV Season",
      "url": "https://finnhub.io/api/news?id=b3c7b91450ed17a018a90770455a683162147cf1fb23ba29b947d00ff060a0ed"
    }
  },
  {
    "ts": null,
    "headline": "Merck's KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China...",
    "url": "https://finnhub.io/api/news?id=c61c91b7436e2331f70952fe8389404c208a220073fe14f05d47cf40c51c45cd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734429687,
      "headline": "Merck's KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC",
      "id": 132025135,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China...",
      "url": "https://finnhub.io/api/news?id=c61c91b7436e2331f70952fe8389404c208a220073fe14f05d47cf40c51c45cd"
    }
  },
  {
    "ts": null,
    "headline": "Merck: FDA to review clesrovimab in RSV",
    "summary": "Merck announced Tuesday that the U.S. Food and Drug Administration has agreed to review its Biologics License Application for clesrovimab for protection against respiratory syncytial virus in...",
    "url": "https://finnhub.io/api/news?id=99471f614d9dc970215f8ec68870d212c9e5a3bdf628cd77a790f4b118ddf43b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734423379,
      "headline": "Merck: FDA to review clesrovimab in RSV",
      "id": 132024081,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced Tuesday that the U.S. Food and Drug Administration has agreed to review its Biologics License Application for clesrovimab for protection against respiratory syncytial virus in...",
      "url": "https://finnhub.io/api/news?id=99471f614d9dc970215f8ec68870d212c9e5a3bdf628cd77a790f4b118ddf43b"
    }
  },
  {
    "ts": null,
    "headline": "Maternal mortality trends remain dire — and researchers face an uphill battle to solve them",
    "summary": "Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.",
    "url": "https://finnhub.io/api/news?id=4aff75fbfde4c744522995c58a6188d4936e75b5ac2a42ef17ce69d24f02da34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734422400,
      "headline": "Maternal mortality trends remain dire — and researchers face an uphill battle to solve them",
      "id": 132034588,
      "image": "https://imgproxy.divecdn.com/2FsXUoaAyBZKvYC0Xk-rUEB7I67Z6nhPO55XnDOvDNo/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDg3NTA0MjMwLmpwZw==.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.",
      "url": "https://finnhub.io/api/news?id=4aff75fbfde4c744522995c58a6188d4936e75b5ac2a42ef17ce69d24f02da34"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate",
    "summary": "By Colin Kellaher Merck & Co. on Tuesday said the Food and Drug Administration has accepted its application seeking approval of its proposed clesrovimab vaccine aimed at protecting infants from...",
    "url": "https://finnhub.io/api/news?id=69138b3a6a18f1152a352a18eff7a2c4a4ee67d284dba49c273aa3be07bf38c5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734420446,
      "headline": "Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate",
      "id": 132023538,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. on Tuesday said the Food and Drug Administration has accepted its application seeking approval of its proposed clesrovimab vaccine aimed at protecting infants from...",
      "url": "https://finnhub.io/api/news?id=69138b3a6a18f1152a352a18eff7a2c4a4ee67d284dba49c273aa3be07bf38c5"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Buy Opportunity Backed By Growth",
    "summary": "Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate MRK stock a strong buy.",
    "url": "https://finnhub.io/api/news?id=8a5135ec862d828d1354b0aa76a5706e4424ec585dc58bf1464648beee7bae8a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734413077,
      "headline": "Merck: Buy Opportunity Backed By Growth",
      "id": 132022536,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate MRK stock a strong buy.",
      "url": "https://finnhub.io/api/news?id=8a5135ec862d828d1354b0aa76a5706e4424ec585dc58bf1464648beee7bae8a"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Phase 3 trials abandoned",
    "summary": "Merck has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody for lung cancer. Vibostolimab is being...",
    "url": "https://finnhub.io/api/news?id=d9aac2a84bb7fe233049a5fae98c6e6f27fba3a9c4ecc3539afd73814407f17b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734404416,
      "headline": "Merck: Phase 3 trials abandoned",
      "id": 132021397,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody for lung cancer. Vibostolimab is being...",
      "url": "https://finnhub.io/api/news?id=d9aac2a84bb7fe233049a5fae98c6e6f27fba3a9c4ecc3539afd73814407f17b"
    }
  }
]